# AUGA: Q2 2022 Results Review

## Despite inflationary pressures, the overall outlook remains positive

Auga Group ('AUGA' or the 'Group') published its Q2 results showing solid growth y-oy and are broadly in line with our expectations. However, individual segments' performances are mixed. The sales growth and profitability drivers have been the crop growing and dairy segment, but Fast Moving Consumer Goods ('FMCG') and mushroom segments have had a more negative impact due to inflationary pressures on costs. The Group reported Q2 sales of EUR 16.43m (+20% y-o-y), but gross profits were EUR 6.78m (+70% y-o-y), reaching 41.3% gross margin (+12pp y-o-y). AUGA has maintained operating costs at a rather stable level considering the inflationary pressures by operating expenses amounting to EUR 2.84m and increasing 8.4% y-o-y in Q2. Accordingly, EBITDA reached EUR 8.34m (+54% y-o-y) leading to an EBITDA margin of 50.7% (+ 11.2pp y-o-y), but operating profits amounted to EUR 4.18m (+176% y-o-y) with operating margin of 25.5% (+ 14.3pp y-o-y). As a result of previous years' low harvest and other pandemic-related negative impacts on other segments' performance, in Q1 2022 the Group took upon additional debt financing of c.a. EUR 10m for working capital requirements and to develop its technological projects. Consequently, financing costs have increased by 21% y-o-y reaching EUR 1.74m in Q2. This certainly will make the Group's net profitability even more sensitive to negative impacts on business segments and costs. The Group maintains high leverage (D/E ratio at end of 6M: 1.3x) due to which financial stability remains fragile in low harvest seasons. Lastly, net profit in Q2 reached EUR 2.44m implying a net margin of 14.9% (+14.3pp y-o-y).

## Crop growing segment

In terms of sales, the crop growing segment showed good improvement despite the low harvest yields last year, i.e. sales growth was driven by the increase in the market price of crops. Sales in Q2 reached EUR 3.76m (+92.7% y-o-y) and reported a gross profit of EUR 6.56m (+60.7% y-o-y). The gross profit has been mainly driven by the revaluation of biological assets at fair value as the market price for crops contracted so far has been considerably high and yields are expected to be much better y-o-y. So far, we expect the crop segment to show better results y-o-y, however, until the crops are not harvested the yield expectations are not set in stone. Furthermore, as the Ukrainian grain export through the Black Sea has somewhat opened the wheat price has come down considerably and reached closer to the pre-war level, thus the segment's profit-ability will also depend on how much AUGA has contracted of the expected harvest at peak prices and further wheat price movements.

## Dairy segment

In Q2, as well as in Q1, the dairy segment's results have considerably improved y-o-y and have been mainly driven by the milk price increase. At end of 6M 2022, the average price of milk sold (per tonne) stood at c.a. EUR 497 (+20.5% y-o-y), at the same time average cost of milk sold (per tonne) has only increased by 2.7% y-o-y reaching

Key Numbers (EURm)	2018	2019	2020	2021	2022E*	2023E*
Sales (EURm)	54.7	71.1	83.1	71.8	88.3	96.0
Sales growth (%)	12.2	29.9	16.8	(13.6)	23.0	8.7
Net profit (EURm)	(6.0)	(3.2)	0.9	(14.8)	1.2	9.5
EPS (EUR)	(0.03)	(0.01)	(0.01)	(0.06)	0.01	0.04
P/E (x)	n.m.	n.m.	n.m.	n.m.	83.5	10.7
Payout per share (EUR)#	-	-	-	-	-	-
Payout yield (%)	-	-	-	-	-	-
P/B (x)	0.9	0.9	1.1	1.4	1.3	1.1
EV/Sales (x)	2.5	2.4	2.3	3.0	2.4	2.2
EV/EBITDA (x)	32.6	10.1	8.8	23.6	11.0	7.6
EV/EBIT (x)	n.m.	171.5	32.5	n.m.	25.1	14.1
ROE (%)	(7.0)	(3.6)	0.9	(17.1)	1.5	11.0

Source: AUGA, LHV \*2021E-2023E multiples are based on the share price (2<sup>nd</sup> June 2022) of EUR 0.4435 per share. <sup>#</sup> Payout per share include dividends and share capital reduction

## **Company Profile**


Listing Market:	Baltic Main List
Bloomberg Ticker:	AUG1L LH
ISIN:	LT0000127466
Industry (Bloomberg):	Consumer Staples
Sector (Bloomberg):	Food, Beverage and Tobacco
Website:	http://www.auga.lt

Share Data, as of 1 <sup>st</sup> Sep 2022				
Current Share Price (EUR):	0.4435			
Fair Value Range, EUR (FVR):	0.61-0.71			
Upside, % (to mid-point of FVR):	48.82			
52-week High/Low (EUR):	0.56/0.40			
3m Avg. Daily Volume (th):	18.40			
Market Cap (EURm):	101.88			
Ordinary Shares (m):	229.71			


# Key Shareholders, as of 30<sup>th</sup> June 2022

Baltic Champs Group, UAB	55.15%
EBRD	8.62%
Žilvinas Marcinkevičius	6.93%

# 12-Month Price Performance



# LHV Fair Value Range: EUR 0.61-0.71\*



\* As of 23rd Dec 2021

AUG1L : Results Review, EURm	Q2/22A	Q2/21A	% у-о-у	Q2/22E	6M/22A	6M/21A	% у-о-у
Net sales	16.43	13.65	20.4	13 to 15.2	33.99	33.13	2.6
Crop Growing	3.76	1.95	92.8	0.6 to 1.3	8.85	9.48	(6.6)
Mushrooms	7.27	7.07	2.8	6.9 to 7.6	14.28	14.33	(0.3)
Dairy	4.09	3.45	18.6	3.9 to 4.3	8.14	6.73	21.0
End-Consumer Packaged Goods	1.31	1.17	11.7	1.6 to 2	2.72	2.59	5.0
Gross profit	6.78	3.99	70.0	5.3 to 7.7	12.43	8.50	46.4
EBITDA	8.34	5.40	54.4		15.05	11.14	35.1
Operating profit	4.18	1.52	175.6	2.4 to 4.8	7.07	3.62	95.3
Net profit	2.44	0.08	2,993.7	0.7 to 3	3.65	0.75	388.8
Gross margin, %	41.3	29.2			36.6	25.6	
EBITDA margin, %	50.7	39.6			44.3	33.6	
Operating margin, %	25.5	11.1			20.8	10.9	
Net margin, %	14.9	0.6			10.7	2.3	

Source: Auga Group, LHV

c.a. EUR 427 at end of 6M, despite the inflationary pressures. This is also reflected in the segment's gross profitability. In Q2, the dairy segment reported sales of EUR 4.1m (+18.7% y-o-y) and a gross profit of EUR 0.72m, compared to a gross loss of EUR 0.47m in Q2 2021. Although the Group has been able to increase its herd in H1 this year up to 3,582 cows (+2.1% y-o-y), the total tonnage of milk products sold decreased by 5.4% y-o-y. The average milk yield in the first half of 2022 remained stable compared to the same period last year. However, milk production in the Q2 of this year decreased by 4% y-o-y. This was due to last year's poor harvest and the consequent loss of this year's feed quality due to a lack of feed ingredients. It is expected that after the new 2022 year harvest, the feed composition of the crop will be updated and the milk yield will return to the previous level. However, we could expect that the yields will only come back at the very end of Q4 as the new harvest will be harvested in Q3 and after the new feed is applied, the yields return gradually in weeks or months. The reasoning for applying lower quality feed might be that the price of feed is significantly higher y-o-y and if the yields show a relatively low drop y-o-y, it might be better to stay with lower yields. Despite the drop in yield, we remain positive outlook going forward.

#### Mushroom segment

2

Segment sales in Q2 increased by 2.8% y-o-y reaching EUR 7.27m, however, the segment made a gross loss of EUR 0.20m, compared to a gross profit of EUR 0.09m in Q2 2021. Although production capacity is returning to normal output levels, the segment has been struggling with negotiating higher prices with clients and inflationary pressures on production costs. While the average price of sold mushrooms per tonne at the end of 6M has increased by c.a. 3% y-o-y reaching EUR 2,294, the average cost of sold mushrooms at the end of 6M increased by 9.5% reaching EUR 2,349, furthermore COGS in Q2 reached EUR 7.4m (+6.6% y-o-y). The cost of mushrooms has shifted upwards due to growing energy and transportation costs that showed an increase of 52% y-o-y (EUR 0.85m). Results are somewhat upsetting, considering that production capacity is returning to previous levels, however, AUGA is not able to reach the desired profitability due to inflationary pressures on costs. If AUGA will be successful in negotiating better prices with its clients, the segment's profitability should return as the production capacity has improved, however, further movements in the cost of

energy and transport will also play a significant role. Due to tight competition in the mushroom market, we might see the mushroom segment struggling to achieve much better prices and positive profitability in the coming quarters as well.

#### FMCG segment

Despite the improved sales growth y-o-y compared to Q1, the FMCG segment's profitability has suffered due to inflationary pressures on costs. Seasonality of sales has caused a delay in the revision of product pricing, therefore, results of the revision should only be seen in Q3. In Q2, FMCG sales amounted to EUR 1.31m (+11.7% y-o-y), however, the COGS increased by 56.9% y-o-y, reaching EUR 1.39m. Consequently, AUGA reported a gross loss of EUR (0.08)m, compared to a gross profit of EUR 0.28m in Q2 2021. As per the Group's comment that given the global surge in inflation and logistics disruptions that pose challenges for projects in Japan and US markets, it is expected that this year's growth plan for the segment will not be met. Although we should expect improvements in Q3 sales growth, profitability improvements are likely to depend on the extent of pricing revision. Overall, we still consider that the FMGC segment has good growth potential in long run, but in near future, it is most likely to report lower profitability as well as sales growth.

#### Overall consideration

Although the Group encounters some profitability struggles in FMCG and mushroom segments, we can expect improvements going forward when product prices are revised, although that is not a simple thing to do, considering the seasonal purchases for the FMCG segment and intense competition in the mushroom segment. Overall, we keep a positive outlook for this year as AUGA's main segment i.e. crop growing segment until now shows substantial improvements y-o-y in selling price and expected yields of crops, considering the favourable weather conditions and crop contract price which reflect in the growth of gain on revaluation of biological assets at fair value recognized in reporting period (+62% y-o-y for 6M 2022). Last but not least, although milk yields have decreased, increased herd and increase in milk prices are offsetting negative effects. The COGS has remained rather stable despite inflationary pressures, and we expect a good performance of this segment going forward.

Contacts: Ivars Bergmanis Head of Institutional Markets Tel: +372 680 2720 Mob: +372 534 11114 ivars.bergmanis@lhv.ee

Valters Smiltāns Analyst valters.smiltans@lhv.ee

Date and time of sign-off: Friday 2<sup>nd</sup> Sep, 16:00

## Disclaimer

З

The copyright in this report belongs to AS LHV Pank (hereinafter 'LHV'). LHV is a full service bank with a focus on the Baltic region. LHV is a member of the Tallinn, Riga, and Vilnius stock exchanges. LHV is under the supervision of the Estonian Financial Supervisory Authority (Finantsinspektsioon; see also www.fi.ee). Readers of this report should be aware of that LHV and LHV affiliated companies (hereinafter 'LHV's Group') are constantly seeking to offer investment banking services to companies (hereinafter, 'Company' or 'Companies') mentioned in research reports or may have other financial interests in those Companies.

AS LHV Pank has made an arrangement with AUGA group ('AUGA'), AB whereby LHV's research analysts independently produce research reports on AUGA group and provide them to AUGA for the purposes of providing more information about AUGA to investors who are not customers of LHV.

AS LHV Pank has made an agreement with EfTEN Real Estate Fund III on commercial terms whereby LHV's research analysts independently produce research reports on EfTEN Real Estate Fund III. In turn, LHV is paid a fixed fee for a certain number of reports on an annual basis.

AS LHV Pank has made an arrangement with MADARA Cosmetics ('MADARA'), whereby LHV's research analysts independently produce research reports on MADARA and provide them to MADARA for the purposes of providing more information about MADARA to investors who are not customers of LHV. MADARA is listed on the Nasdaq Baltic First North List. In addition to being the certified adviser for MADARA, LHV is also the certified adviser for Linda Nektar ('LINDA') on Nasdaq Baltic First North on an ongoing fee-based arrangement

LHV's Group acts as a market maker /(and)/ liquidity provider for TKM1T, APG1L, TVEAT, HMX1R, LINDA, MDARA, DGR1R, and VIRSI.

All reports are produced by LHV's research department. In order to proactively prevent conflicts of interest, LHV has established several procedural and physical measures. Such measures include, among other things, confidentiality measures through separation, or so-called "Chinese walls", virtual and physical barriers to limit the exchange of information between different departments, groups or individuals within LHV Group. These measures are monitored by the compliance department of LHV. LHV does everything possible to avoid the conflict of interests but it cannot guarantee that conflict of interests situations do not arise at all.

LHV provides coverage on this company on a regular basis, therefore this report may include assumptions and findings laid out in greater detail elsewhere. If interested, clients may approach LHV for these previous reports.

In October 2021, AS LHV Pank was the Global Lead Manager for the IPO of AS DelfinGroup on Nasdaq Riga. AS LHV Pank has made an arrangement with AS Delfin-Group ('DelfinGroup'), whereby LHV's research analysts independently produce research reports on DelfinGroup and provide them to DelfinGroup for the purposes of providing more information about DelfinGroup to investors who are not customers of LHV. AS LHV Pank is also a market maker for the shares of DelfinGroup.

In November 2021 AS LHV Pank was the Global Lead Manager for the IPO of AS Hepsor on Nasdaq Tallinn. LHV Pank has made an arrangement with AS Hepsor, whereby LHV's research analysts independently produce research reports on Hepsor, and provide them to Hepsor, for the purposes of providing more information about Hepsor, to investors who are not customers of LHV.

In November 2021, AS LHV Pank was the Global Lead Manager for the IPO of Virši-A ('VIRSI') on A to Nasdaq First North Riga. AS LHV Pank has made an arrangement with VIRSI, whereby LHV's research analysts independently produce research reports on VIRSI and provide them to VIRSI for the purposes of providing more information about VIRSI to investors who are not customers of LHV. AS LHV Pank is also a market maker for the shares of VIRSI. LHV is also the certified adviser for VIRSI on Nasdaq Baltic First North on an ongoing fee-based arrangement.

In November 2021, AS LHV Pank was the Global Lead Manager for the private placement of the first (EUR 3m) tranche of a EUR 10m bond programme for SIA CrossChem and subsequent admission to trading on Nasdaq First North Riga. AS LHV Pank has made an arrangement with CrossChem,

#### **Baltic Review**

whereby LHV's research analysts independently produce research reports on CrossChem and provide them to CrossChem for the purposes of providing more information about CrossChem to investors who are not customers of LHV. LHV is also the certified adviser for CrossChem on Nasdaq Baltic First North on an ongoing fee-based arrangement.

In December 2021, AS LHV Pank was the Global Lead Manager for the IPO of TextMagic on Nasdaq First North Tallinn. AS LHV Pank has made an arrangement with TextMagic, whereby LHV's research analysts independently produce research reports on TextMagic and provide them to TextMagic for the purposes of providing more information about TextMagic to investors who are not customers of LHV.

This report is based upon information available to the general public. The information contained within has been compiled from sources deemed to be suitably reliable. However, no guarantee to that effect is given and henceforth neither the accuracy, completeness, nor the timeliness of this information should be relied upon. Any opinions expressed herein reflect a professional judgment of market conditions as at the date of publication of this document and are therefore subject to change without prior notice.

LHV reviews its estimates at least once during financial reporting period and upon most major financial events.

The report is not intended for public distribution and may not be reproduced, redistributed or published in any form whatsoever (in whole or in part) without prior written permission of LHV. The user shall be liable for any non-authorised reproduction or use of this report, whether in whole or in part, and such, reproduction may lead to legal proceedings. LHV does not accept any liability whatsoever for the actions of third parties in this respect. This information may not be used to create any financial instruments or products or any indices.

Neither LHV nor its directors nor its representatives nor its employees will accept liability for any injuries, losses or damages, direct or consequential caused to the reader that may result from the reader's acting upon or using the content contained in the publication.

The analyst(s) of this report hereby confirm that the views expressed in this report accurately reflect their personal views about the Companies and securities covered at the time of publication. The authors further confirm that they have not been, nor are nor will be receiving direct or indirect compensation in exchange for expressing any of the views contained in the report.

The analysts receive remuneration based on among others, the overall group revenues of LHV, including investment banking revenues. However, no compensation is based on a specific investment banking transaction. Trading with securities which are covered by a report is subject to strict compliance with internal rules governing own-account trading by staff members and third parties acting for the account of such staff members.

This research report is produced for the private information of recipients and LHV is not advising nor soliciting any action based upon it. If you are not a client of LHV, you are not entitled to this research report.

This report does not by any means constitute an offer or a solicitation, nor a recommendation to purchase or sell securities, commodities, currencies or other investments referred to herein.

This report does not constitute independent investment advice. LHV does not assume any fiduciary responsibility or liability for any consequence, financial or otherwise, arising from any investment or disinvestment decision taken on the basis of this report. It has been prepared without regard to the individual financial circumstances and objectives of those who receive this report. The securities referred to in this report may not be suitable for all investors.

Investors should independently and carefully evaluate every particular investment and seek the advice of a financial adviser if needed.

The analysis contained in this research report is based on numerous assumptions; different assumptions could result in materially different results. Any valuations, projections and forecasts contained in this report are based on a number of assumptions and estimates and are subject to contingencies and uncertainties. The inclusion of any such valuations, projections and forecasts in this report should not be regarded as a representation or warranty by or on behalf of LHV or any person within LHV that such valuations, projections and forecasts or their underlying assumptions and estimates will be met or realised.

Past performance is not a reliable indicator of future returns.

4

Where an investment is described as being likely to yield income, please note that the amount of income that the investor will receive from such an investment may fluctuate due to currency exchange rate moves and taxation considerations specific to that investor.

The information contained in this report does not constitute advice on the tax consequences of making any particular investment decision.

The fair value range has been issued for a 12-18 month period and has been derived from a weighted approach combining both DCF valuation and relative multiple comparisons. The relative multiple comparisons further incorporate additional weighting considerations relating to the underlying metrics

5

and time forecast periods. Company specific inputs have been forecast and a list of peer companies has been compiled by the LHV analyst(s) writing this research commentary, whereas the consensus peer data has been obtained from Bloomberg.

For more detailed information about the valuation methods please contact the analyst(s) using the contact details provided above. For a useful summary of our coverage of this company, including the current sensitivity analysis, please refer to our latest monthly product: The Baltic Equity Companion. Alternatively you can also contact the analyst(s) using the contact details provided above.

Although we do not issue explicit recommendations, for regulation compliance purposes we adhere to the following synthetic structure:

- Buy- Expected return of more than 10% within 12-18 months (including dividends)
- Neutral- Expected return from -5% to 10% within 12-18 months (including dividends)
- Sell- Expected return less than -5% within 12-18 months (including dividends)

In the 12-month period preceding 31.03.2022 LHV has issued recommendations, of which 29.3% have been 'Buy recommendations', 19,5% as 'Neutral', 24.4% as 'Sell' and 26.8% as 'under review'. Of all the 'Buy recommendations' issued, 37.5% have been for companies for which LHV has provided investment banking services in the preceding 12-month period. Of all the 'Neutral recommendations' issued, 6.3% have been issued to companies for which LHV has provided investment banking services in the preceding 12-month period. The classification is based on the above structure.

For a list of recommendations that were disseminated during the preceding 12-month period, including the date of dissemination, the identity of the person(s) who produced the recommendation, the price target and the relevant market price at the time of dissemination, the direction of the recommendation and the validity time period of the price target, please contact the analyst(s) using the contact details provided above.